STUTTGART, Germany, November 11, 2016 /PRNewswire/ -- There's a lot happening at Haselmeier! As the next step in the consistent reorganisation process of the Haselmeier Group, some activities are being moved to other locations to guarantee greater focus on strategic and operative tasks. As a result, the Sales and Marketing department shall relocate from Zurich to Stuttgart, thus coming closer to the Development department and becoming a part of the new sales company Wilhelm Haselmeier GmbH & Co. KG. In future, the facility in Switzerland shall focus more strongly on strategic planning, innovation and intellectual property. The Order Processing, which is currently a part of Haselmeier AG in Switzerland, shall also be active in Germany and shall be integrated into the Order Management department there. Haselmeier sees itself as a strategic partner to pharmaceutical and biotechnological companies for the development and production of innovative application devices for drugs with the aim of improving the lives of patients. In the course of the restructuring process, the medical devices company shall be more focussed on the needs of its customers. To achieve this, processes and structures are being sustainably controlled internally so that customers can be guaranteed more customised solutions. We are happy to announce that the Group's Executive Board is now complete with the appointment of a new Chief Technology Officer (CTO) and Chief Business Officer (CBO). Haselmeier welcomes Thomas Dürkop as the Head of Applied Development, Project Management and Industrialisation and Dr. Fred Metzmann as the Head of Key Account Management, Marketing and Global Business Development - two experts, who shall also spur the reorientation of the new company philosophy with their long-standing experience and competency. About Haselmeier: Haselmeier stands for the development and production of innovative self-injection devices with award-winning designs. The Haselmeier Group primarily works on behalf of pharmaceutical and biotechnology companies to improve the lives of patients by manufacturing pens and auto-injectors that are easy to use and that can be dosed with precision. The family business covers all steps-from design to planning to industrialisation-in the creation of high-quality self-injection systems.